Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 154Neoplasm Metastasis 10Prostatic Neoplasms, Castration-Resistant 8Neoplasms 6Metastatic Castration-resistant Prostate Cancer 6Breast Neoplasms 6Metastatic Castration Resistant Prostate Cancer 5Prostate Cancer Metastatic 4Metastatic Castration-Resistant Prostate Cancer 4Urogenital Neoplasms 2Prostatic Diseases 2Neoplasms by Site 2Metastatic Castration-resistant Prostate Cancer (mCRPC) 2Genital Neoplasms, Male 2Castration-resistant Prostate Cancer 2Carcinoma, Non-Small-Cell Lung 2Adenocarcinoma 2Urinary Bladder Neoplasms 1Stage II Prostate Adenocarcinoma 1Salivary Glands Tumors 1Rate of PSA Response in Oligometastatic,CRPC Undergoing SBRT in Combination With Abiraterone Acetate (AA), Compared to Patients Treated With AA Alone 1Prostate Adenocarcinoma 1Pharmacogenetic Study 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Ovarian Neoplasms 1Oligometastatic Prostate Carcinoma 1Newly Diagnosed Oligometastatic Prostate Cancer 1Neoadjuvant Therapy 1NSCLC Harboring NRG1 Fusion 1Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 1

Interventions

pembrolizumab 2Injections 2Abiraterone Acetate 2radium Ra 223 dichloride 1niraparib 1enzalutamide 1efineptakin alfa 1darolutamide 1capivasertib 1cabazitaxel 1apalutamide 1abiraterone 1Solutions 1Prednisone 1Lutetium-177 1Lutetium 1Docetaxel 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Metastatic Castration-resistant Prostate Cancer (mCRPC) × Abiraterone Acetate × Clear all
NCT03903835 2025-04-09

ProBio

Karolinska Institutet

Phase 3 Recruiting
750 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT04862091 2022-03-04

Comparative Study of Abiraterone Acetate Tablets (I) or ZYTIGA® in Patients With Metastatic Castration-resistant Prostate Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Completed
69 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer (mCRPC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡